Alimera again submits DME drug Iluvien for U.S. approval

Alimera Sciences plans to resubmit Iluvien, a drug candidate for chronic diabetic macular edema, for FDA approval by the end of this month. Alimera licensed the drug from pSivida. The application will highlight the drug's safety profile and will focus on chronic DME patients who don't respond satisfactorily to existing treatments. The drug has been approved in the U.K., Germany, France and several other European countries. In 2011, the FDA requested additional trials.

View Full Article in:

ProactiveInvestors.co.au (Australia) · Australian Life Scientist

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ